Hikma Pharmaceuticals PLC operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Hikma Pharmaceuticals PLC with three other
companies in this sector in the United Kingdom:
sales of £664.95 million [US$814.89 million]
of which 100%
was Buprenorphine Based Drugs),
(£367.80 million [US$450.74 million]
of which 36%
was Licensing & Biotechnology), and
Croda International Plc
(£1.08 billion [US$1.33 billion]
of which 35%
was Personal Care).
Hikma Pharmaceuticals PLC reported sales of £944.31 million (US$1.16 billion)
December of 2015.
increase of 4.4%
versus 2014, when the company's sales were £904.67 million.
Sales at Hikma Pharmaceuticals PLC have increased during each of the previous five years
(and since 2010, sales have increased a total of 100%).
Sales of Branded Pharmaceuticals saw an increase
that was more than double the company's growth rate: sales were up
11.7% in 2015, from
£334.77 million to £373.79 million.
Hikma Pharmaceuticals PLC also saw significant increases in sales in
Injectable Pharmaceuticals (up 7.5% to £465.60 million)
Others (up 7.9% to £5.90 million)
Not all segments of Hikma Pharmaceuticals PLC experienced an increase in sales in 2015:
sales of Generic Pharmaceuticals fell 24.5% to £99.02 million.